Tech Company Financing Transactions
Kupando Funding Round
Remiges Ventures, Brandenburg Kapital and High-Tech Gründerfonds invested in a $12.5 million Series A funding round for Kupando. The round was announced on 9/26/2022.
Transaction Overview
Company Name
Announced On
9/26/2022
Transaction Type
Venture Equity
Amount
$12,450,000
Round
Series A
Investors
Remiges Ventures (Lead Investor) (Kazuhiko Nonomura)
Brandenburg Kapital (Thomas Krause)
Proceeds Purpose
The funds will be used to complete IND-enabling work and to initiate the clinical development of Kupando's lead candidate KUP101 in a solid tumor indication.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Willy-Brandt-Platz 2
Schönefeld, 12529
DE
Schönefeld, 12529
DE
Phone
Undisclosed
Website
Email Address
Overview
KUPANDO is a pioneering Berlin-based biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Pierre Morgon
Chief Executive Officer
Johanna Holldack
Chief Financial Officer
Angelika Leppert
Browse more venture capital transactions:
Prev: 9/26/2022: Faraday Future venture capital transaction
Next: 9/26/2022: Perch Insights venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs